

Nakhle S Saba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8715681/publications.pdf>

Version: 2024-02-01

67
papers

1,902
citations

471509
17
h-index

254184
43
g-index

67
all docs

67
docs citations

67
times ranked

3192
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2015, 16, 169-176.	10.7	344
2	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2014, 74, 2520-2532.	0.9	207
3	A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. <i>Science Advances</i> , 2021, 7, .	10.3	175
4	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018, 131, 2357-2366.	1.4	166
5	Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. <i>Blood</i> , 2016, 128, 82-92.	1.4	141
6	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2015, 100, 1571-1578.	3.5	137
7	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia</i> , 2017, 31, 1340-1347.	7.2	103
8	Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. <i>Nature Nanotechnology</i> , 2021, 16, 1039-1044.	31.5	90
9	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018, 132, 521-532.	1.4	81
10	Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2016, 152, 698.	4.1	42
11	Bortezomib in Plasmablastic Lymphoma: A Case Report and Review of the Literature. <i>Onkologie</i> , 2013, 36, 287-291.	0.8	41
12	MALT1 Inhibition Is Efficacious in Both Na $\tilde{\text{A}}$ -ve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2017, 77, 7038-7048.	0.9	41
13	Cancer and COVID-19: analysis of patient outcomes. <i>Future Oncology</i> , 2021, 17, 3499-3510.	2.4	28
14	COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2354-2356.	2.4	27
15	The utility of hyperbaric oxygen therapy in post-transplant cyclophosphamide-induced hemorrhagic cystitis: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 1.	0.8	23
16	Adalimumab-Induced Acute Myelogenic Leukemia. <i>Southern Medical Journal</i> , 2008, 101, 1261-1262.	0.7	21
17	Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	21
18	Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs. <i>PLoS ONE</i> , 2013, 8, e75252.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-Induced Hyperpigmentation of the Tongue. New England Journal of Medicine, 2011, 365, e20.	27.0	17
20	Do mantle cell lymphomas have an "Achilles heel"? Current Opinion in Hematology, 2014, 21, 350-357.	2.5	17
21	Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.. Blood, 2012, 120, 2899-2899.	1.4	16
22	Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. Transfusion Medicine, 2021, 31, 217-220.	1.1	15
23	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. Blood, 2018, 132, 147-147.	1.4	12
24	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
25	Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation. Blood, 2012, 120, 1789-1789.	1.4	10
26	Disruption of pre-B-cell receptor signaling jams the WNT/ β -catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. Leukemia Research, 2015, 39, 1220-1228.	0.8	9
27	Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C? inhibitor. Leukemia and Lymphoma, 2011, 52, 877-886.	1.3	8
28	Protein Kinase C-Beta Inhibition Induces Apoptosis and Inhibits Cell Cycle Progression in Acquired Immunodeficiency Syndrome-Related Non-Hodgkin Lymphoma Cells. Journal of Investigative Medicine, 2012, 60, 29-38.	1.6	8
29	Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e105-e112.	0.4	8
30	Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia. Blood, 2013, 122, 3819-3819.	1.4	8
31	High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. Leukemia Research, 2021, 106, 106582.	0.8	6
32	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. Targeted Oncology, 2021, 16, 761-771.	3.6	5
33	Quantitative assessment of chromosome instability induced through chemical disruption of mitotic progression. Cell Cycle, 2016, 15, 1706-1714.	2.6	4
34	Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.. Leukemia Research Reports, 2021, 15, 100247.	0.4	4
35	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. Leukemia Research, 2021, 101, 106514.	0.8	4
36	Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen. Leukemia Research, 2021, 106, 106583.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning. European Journal of Haematology, 2017, 99, 56-59.	2.2	3
38	The prognostic implications of tetraploidy/near-Tetraploidy in acute myeloid leukemia: a case series and systematic review of the literature. Leukemia and Lymphoma, 2021, 62, 203-210.	1.3	3
39	A Systemic Review of CD5-Negative Mantle Cell Lymphoma Identifies Potential Clinical and Biological Implications. Blood, 2016, 128, 3048-3048.	1.4	3
40	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
41	Cancer of the Indiana Pouch: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2013, 11, e30-e34.	1.9	2
42	Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). Leukemia and Lymphoma, 2021, 62, 2539-2542.	1.3	2
43	Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NF- κ B Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma. Blood, 2013, 122, 82-82.	1.4	2
44	CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. Leukemia and Lymphoma, 2022, 63, 911-917.	1.3	2
45	Adjuvant High-Dose Interferon- α for Resected Melanoma in a Patient with HIV Infection. Oncologist, 2010, 15, 695-698.	3.7	1
46	Neutrophil numerals. Blood, 2014, 123, 1635-1635.	1.4	1
47	Reduction in Cell Viability and in Homeobox Protein Levels Following in Vitro Exposure to α -tocopherol in Acute Myeloid Leukemia. Nutrition and Cancer, 2016, 68, 530-534.	2.0	1
48	A centrocyte blood count of a quarter million. American Journal of Hematology, 2017, 92, 972-973.	4.1	1
49	Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell Lymphoma: A multi-institution retrospective analysis and systematic review. Leukemia Research Reports, 2021, 16, 100263.	0.4	1
50	COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients. Blood, 2020, 136, 40-41.	1.4	1
51	A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1418-1418.	1.4	1
52	COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality. Blood, 2020, 136, 6-7.	1.4	1
53	CRISPR-based Assay Reveals SARS-CoV-2 RNA Dynamic Changes and Redistribution Patterns in Non-Human Primate Model. Emerging Microbes and Infections, 2022, , 1-24.	6.5	1
54	Vitamin E Isoforms Inhibit Cell Proliferation and Downregulate Homeobox Protein Expression in the Leukemic KG-1 Cells.. Blood, 2007, 110, 4304-4304.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Selective Protein Kinase C \hat{I}^2 Inhibition Induces Apoptosis and Arrests Cell Cycle in AIDS-Related Non-Hodgkin Lymphoma Cell Lines.. Blood, 2009, 114, 4807-4807.	1.4	0
56	Effect of Protein Kinase C \hat{I}^2 Specific Inhibition On Acute Lymphoblastic Leukemia Cell Lines.. Blood, 2009, 114, 4817-4817.	1.4	0
57	Enzastaurin Induces Apoptosis and Cell Cycle Arrest in B-Cell Acute Lymphoblastic Leukemia Cell Lines Through AKT Pathway Inhibition and $\hat{A}^{\hat{Y}}$ -Catenin Accumulation. Blood, 2012, 120, 1350-1350.	1.4	0
58	The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment. Blood, 2012, 120, 865-865.	1.4	0
59	Direct in Vivo Evidence of Increased Chronic Lymphocytic Leukemia Cell Proliferation in Lymph Nodes Compared to Bone Marrow and Peripheral Blood. Blood, 2012, 120, 184-184.	1.4	0
60	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. Blood, 2013, 122, 3760-3760.	1.4	0
61	Ongoing Activation of the BCR, NF $\hat{I}^{\hat{B}}$, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironment. Blood, 2014, 124, 2991-2991.	1.4	0
62	Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 487-487.	1.4	0
63	Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF- $\hat{I}^{\hat{B}}$ Pathway in Chronic Lymphocytic Leukemia Primary Cells. Blood, 2016, 128, 1597-1597.	1.4	0
64	Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma. Blood, 2016, 128, 4644-4644.	1.4	0
65	The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1288-1288.	1.4	0
66	Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 2908-2908.	1.4	0
67	Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351. Blood, 2020, 136, 19-19.	1.4	0